A single administration of the psychedelic compound dimethyltryptamine (DMT) yielded rapid and enduring reductions in depressive symptoms during a limited clinical study. DMT, known for its potent and fast-acting psychedelic properties, is derived from a variety of plants globally. International regulations classify it as a substance with a high potential for misuse and no recognized medical applications.
However, a growing body of observational research indicates that DMT, along with other psychedelics, may offer therapeutic benefits for individuals with severe mental health conditions, particularly those unresponsive to conventional therapies.
Study Design and Participants
The recent investigation involved 34 participants who had experienced moderate to severe depression for an average of 10 years. These individuals had previously undergone at least two unsuccessful treatment regimens involving conventional medicine or psychotherapy. The research team, led by David Erritzoe of Imperial College London, administered treatments alongside psychotherapeutic support.
Half of the participants received a substantial 21.5-gram intravenous dose of DMT over a 10-minute period. The remaining participants were given a placebo infusion.
Key Findings on Depression Scores
All participants completed a depression-rating questionnaire at the outset of the study. Two weeks post-infusion, the group that received DMT demonstrated a statistically significant decrease in depression scores, averaging 7.4 points more than the placebo group. This improvement was sustained over a three-month period, with some participants experiencing benefits for up to six months.
Single Dose Efficacy
In a subsequent phase of the trial, participants had the option to receive a further dose of DMT, either as a second dose for those initially receiving DMT, or as their first dose for the placebo group, again with therapist support. This additional treatment did not lead to significant improvements beyond those observed after the initial dose. This suggests that a single treatment session may be sufficient to achieve lasting effects.
Safety and Tolerability
Regarding safety, the observed side effects were generally mild. Some participants reported transient experiences of anxiety, nausea, and discomfort at the infusion site.
Expert Commentary and Future Implications
“We have demonstrated that a single DMT experience, lasting approximately 25 minutes, can be administered safely, is well-tolerated, and is linked to significant improvements in depression that appear to extend beyond the immediate psychedelic state,” stated Erritzoe. He noted the promising comparability of these early findings to results from studies involving longer-acting psychedelics like psilocybin. The prospect of a shorter psychedelic experience could potentially reduce treatment costs, Erritzoe added.
However, the distinct nature of psychedelic experiences means individuals can often discern whether they received the active drug or a placebo. This potential for expectation bias could influence the observed outcomes, blending both the drug’s pharmacological effects and participant expectations.
Mystical Experiences and Therapeutic Benefit
The researchers observed a correlation between the intensity of mystical-type experiences reported by the DMT group approximately 25 minutes post-administration and the degree of their therapeutic improvement. Team member Tommaso Barba, also from Imperial, explained, “The greater a person’s sense of unity, a profound positive emotional shift, alterations in their perception of time and space, and experiences deemed too profound for words, the more benefit they tended to report afterwards.”
Potential Mechanisms of Action
While the precise mechanisms by which psychedelics like DMT contribute to treating depression remain under investigation, current research suggests they may facilitate a temporary period of neuroplasticity, enabling the brain to form new connections. Alternatively, they might reduce inflammation, which has been linked to mental health issues.
Considerations for Future Research
Rick Strassman, a prominent figure in psychedelic research, indicated that these findings build upon prior studies where participants were informed about the substance they were receiving. Nevertheless, he emphasized the necessity of proceeding with caution. Strassman noted, “While the DMT experience is shorter than that of psilocybin and LSD, it can be considerably more disorienting than longer-acting psychedelics and necessitates meticulous preparation, monitoring, and follow-up.”
Next Steps and Related Research
Erritzoe and his team plan to leverage these findings to inform their ongoing trials of a modified DMT compound, HLP004, for anxiety. Concurrently, a related molecule, 5-MeO-DMT, is in a more advanced testing phase for depression. For example, positive outcomes reported by the firm AtaiBeckley in New York are facilitating the expedited development of their candidate for treatment-resistant depression, making US approval a likely prospect.